Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 400-411

  Spracklin, Douglas K ^a   Hankins, Douglas C ^a   Fisher, Jeannine M ^a   Thummel, Kenneth E ^a   Kharasch, Evan D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; BROMIDE; COUMARIN; CYTOCHROME P450; HALOTHANE; METHOXSALEN; TRIFLUOROACETIC ACID;

ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; LIVER MICROSOME; LIVER NECROSIS; LIVER TOXICITY; OXIDATION; PRIORITY JOURNAL;

ANESTHETICS, INHALATION; CYTOCHROME P-450 CYP2E1; HALOTHANE; HUMANS; MICROSOMES, LIVER; OXIDATION-REDUCTION; RECOMBINANT PROTEINS;

EID: 0030924897     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. AKITA, S., KAWAHARA, M., TAKESHITA, T., MORIO, M. AND FUJII, K.: Halothane-induced hepatic microsomal lipid peroxidation in guinea pigs and rats. J. Appl. Toxicol. 9: 9-14, 1989.
2. ANDERSEN, M. E., GARGAS, M. L., CLEWELL III, H. J. AND SEVERYN, K. M.: Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. Toxicol. Appl. Pharmacol. 89: 149-157, 1987.
3. 2-isoprostanes. Anesthesiology 84: 910-916, 1996.
4. BROWN, A. P. AND GANDOLFI, A. J.: Glutathione-S-transferase is a target for covalent modification by a halothane reactive intermediate in the guinea pig liver. Toxicology 89: 35-47, 1994.
5. BROWN, R. M., TATEISHI, T., GUENGERICH, F. P., WOOD, M. AND WOOD, A. J. J.: Halothane microsomal oxidation is inhibited by diethyldithiocarbamate, an inhibitor of CYP2E1. Anesth. Analg, 80: S59, 1995.
6. CAHALAN, M. K., JOHNSON, B. H. AND EGER II, E. I.: Relationship of concentrations of halothane and enflurane to their metabolism and elimination in man. Anesthesiology 54: 3-8, 1981.
7. CAHALAN, M. K., JOHNSON, B. H., EGER II, E. I., SHEINER, L. B., RICHARDSON, C. A., VARNER, J. K. AND SEVERINGHAUS, J. W.: A noninvasive in vivo method of assessing the kinetics of halothane metabolism in humans. Anesthesiology 57: 298-302, 1982.
8. CARPENTER, R. L., EGER II, E. I., JOHNSON, B. H., UNADKAT, J. D. AND SHEINER, L. B.: The extent of metabolism of inhaled anesthetics in humans. Anesthesiology 65: 201-205, 1986.
9. CASCORBI, H. F., BLAKE, D. A. AND AND HELRICH, M.: Differences in the biotransformation of halothane in man. Anesthesiology 32: 119-123, 1970.
10. CHRIST, D. D., KENNA, J. G., KAMMERER, W., SATOH, H. AND POHL, L. R.: Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 69: 833-838, 1988a.
11. CHRIST, D. D., SATOH, H., KENNA, J. G. AND POHL, L. R.: Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab. Dispos. 16: 135-140, 1988b.
12. COUSINS, M. J., PLUMMER, J. L. AND HALL, P. M.: Risk factors for halothane hepatitis. Aust. N.Z. J. Surg. 59: 5-14, 1989.
13. DE GROOT, H. AND NOLL, T.: Halothane hepatotoxicity: Relation between metabolic activation, hypoxia, covalent binding, lipid peroxidation and liver cell damage. Hepatology 3: 601-606, 1983.
14. ECKES, L. AND BUCH, H. P.: Influence of disulfiram, diethyldithiocarbamate and carbon disulfide on the metabolic formation of trifluoroacetic acid from halothane in the rat. Arzneim. Forsch. 35: 1447-1451, 1985.
15. EGER, R. AND EGER II, E. I.: Effect of temperature and age on the solubility of enflurane, halothane, isoflurane, and methoxyflurane in human blood. Anesth. Analg. 64: 640-642, 1985.
16. ESTABROOK, R. W., PETERSON, J., BARON, J. AND HILDEBRANDT, J.: The spectro-photometric measurement of turbid suspensions of cytochromes associated with drug metabolism. Methods Pharmacol. 2: 303-350, 1972.
17. GRUENKE, L. D., KONOPKA, K., KOOP, D. R. AND WASKELL, L. A.: Characterization of halothane oxidation by hepatic microsomes and purified cytochromes P-450 using a gas Chromatographic mass spectrometric assay. J. Pharmacol. Exp. Ther. 246: 454-459, 1988.
18. GUT, J., CHRISTEN, U., FREY, N., KOCH, V. AND STOFFLER, D.: Molecular mimicry in halothane hepatitis: Biochemical and structural characterization of lipoylated autoantigens. Toxicology 97: 199-224, 1995.
19. JEFCOATE, C. R. E., GAYLOR, J. L. AND CALABRESE, R. L.: Ligand interactions with cytochrome P-450. I. Binding of primary amines. Biochemistry 8: 3455-3463, 1969.
20. JENNER, M. A., PLUMMER, J. L. AND COUSINS, M. J.: Influence of isoniazid, phenobarbital, phenytoin, pregnenolone 16-α-carbonitrile, and β-naphthoflavone on halothane metabolism and hepatotoxicity. Drug Metab. Dispos. 18: 819-822, 1990.
21. KENNA, J. G., MARTIN, J. L., SATOH, H. AND POHL, L. R.: Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug. Metab. Dispos. 18: 788-793, 1990.
22. KENNA, J. G., NEUBERGER, J. AND WILLIAMS, R.: Specific antibodies to halothane-induced liver antigens in halothane-associated hepatitis. Br. J. Anaesth. 59: 1286-1290, 1987.
23. KHARASCH, E. D., HANKINS, D., MAUTZ, D. AND THUMMEL, K. E.: Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 347: 1367-1371, 1996.
24. KHARASCH, E. D., THUMMEL, K., MHYRE, J. AND LILLIBRIDGE, J.: Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin. Pharmacol. Ther. 53: 643-650, 1993.
25. KHARASCH, E. D. AND THUMMEL, K. E.: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 79: 795-807, 1993.
26. KUNZE, K. L., WIENKERS, L. C., THUMMEL, K. E. AND TRAGER, W. F.: Warfarin-fluconazole I. Inhibition of the human P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab. Dispos. 24: 414-421, 1996.
27. LIND, R. C. AND GANDOLFI, A. J.: Concentration-dependent inhibition of halothane biotransformation in the guinea pig. Drug Metab. Dispos. 21: 386-389, 1993.
28. LIND, R. C., GANDOLFI, A. J. AND HALL, P. D. L. M.: Isoniazid potentiation of a guinea pig model of halothane-associated hepatotoxicity. J. Appl. Toxicol. 10: 161-165, 1990.
29. LOESCH, J., SIEGERS, C.-P. AND YOUNES, M.: Influence of cimetidine and diethyldithiocarbamate on the metabolism of halothane and methoxyflurane in vitro. Pharmacol. Res. Commun, 19: 395-403, 1987.
30. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
31. MAENPAA, J., JUVONEN, R., RAUNIO, H., RAUTIO, A. AND PKLKONEN, O.: Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem. Pharmacol. 48: 1363-1369, 1994.
32. MILES, J. S., MCLAREN, A. W., FORRESTER, L. M., GLANCEY, M. J., LANG, M. A. AND WOLF, C. R.: Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267: 365-371, 1990.
33. MIMURA, M., BABA, T., YAMAZAKI, H., OHMORI, S., INUI, Y., GONZALEZ, F. J., GUENGERICH, F. P. AND SHIMADA, T.: Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21: 1048-1056, 1993.
34. MULLER, R. AND SRIER, A.: Modification of liver microsomal lipids by halothane metabolites; a multi nuclear NMR spectroscopic study. Naunyn-Schmiedeberg Arch. Pharmacol. 321; 234-237, 1982.
35. NAKAJIMA, T., WANG, R.-S., ELOVAARA, E., PARK, S. S., GELBOIN, H. V. AND VAINIO, H.: A comparative study on the contribution of cytochrome P450 isozymes to metabolism of benzene, toluene and trichloroethylene in rat liver. Biochem. Pharmacol. 43: 251-257, 1992.
36. NAKAJIMA, T., WANG, R.-S., MURAYAMA, N. AND SATO, A.: Three forms of trichloroethylene-metabolizing enzymes in rat liver induced by ethanol, phenobarbital, and 3-methylcholanthrene. Toxicol. Appl. Pharmacol. 102: 546-552, 1990.
37. POHL, L. R., KENNA, J. G., SATOH, H., CHRIST, D. D. AND MARTIN, J. L.: Neoantigens associated with halothane-hepatitis. Drug. Metab. Rev. 20: 203-217, 1989.
38. RAY, D. C. AND DRUMMOND, G. B.: Halothane hepatitis, Br. J. Anaesth. 67: 84-99, 1991.
39. RICE, S. A., MAZE, M. R., SMITH, C. M., KOSEK, J. C. AND MAZZE, R. I.: Halothane hepatotoxicity in Fischer 344 rats pretreated with isoniazid. Toxicol. Appl. Pharmacol. 87: 411-419, 1987.
40. SATO, N., FUJII, K., YUGE, O. AND MORIO, M.: The association of halothane-induced lipid peroxidation with the anaerobic metabolism of halothane: An in vitro study in guinea pig liver microsomes. Hiroshima J. Med, Sci. 39: 1-6, 1990.
41. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
42. SPRACKLIN, D. K., THUMMEL, K. E. AND KHARASCH, E. D.: Human Reductive Halothane Metabolism in vitro is Catalyzed by P450 2A6 and 3A4. Drug Metab. Dispos. 24: 976-983, 1996.
43. THUMMEL, K. E., KHARASCH, E. D., PODOLL, T. AND KUNZE, K.: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21: 350-357. 1993.
44. THUMMEL, K. E., O'SHEA, D., PAINE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D. AND WILKINSON, G. R.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59: 491-502, 1996.
45. VINEGAR, A., WILLIAMS, R. J., FISHER, J. W. AND MCDOUGAL, J. N.: Dose-dependent metabolism of 2,2-dichloro-1,1,1,-trifluoroethane: A physiologically based pharmacokinetic model in the male Fischer 344 rat. Toxicol. Appl. Pharmacol. 129: 103-113, 1994.
46. YAMANO, S., NHAMBURO, P. T., AOYAMA, T., MEYER, U., INABA, T., KALOW, W., GELBOIN, H. V., MCBRIDE, O. W. AND GONZALEZ, F. J.: cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: Identification of a normal and two variant cDNA-derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28: 7340-7348, 1989.